Rules for identifying patients at increased risk for candidal infections in the surgical intensive care unit: Approach to developing practical criteria for systematic use in antifungal prophylaxis trials

Medical Mycology

Volumn 43, Issue 3, 2005, Pages 235-243

  Paphitou, Niki I ^a,b   Ostrosky Zeichner, Luis ^a   Rex, John H ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b NONE   (Canada)

Author keywords

Antifungal prophylaxis; Candidal infections; Criteria; Intensive care unit; Predictive rules

Indexed keywords

ABDOMINAL SURGERY; ADOLESCENT; ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; CANDIDIASIS; DIABETES MELLITUS; DISEASE CLASSIFICATION; FEMALE; HEMODIALYSIS; HIGH RISK PATIENT; HOSPITAL PATIENT; HOSPITALIZATION; HUMAN; INFECTION RISK; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; MALE; PARENTERAL NUTRITION; PREDICTION; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; VEIN CATHETERIZATION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBIOTIC PROPHYLAXIS; CANDIDIASIS; DIABETES MELLITUS; FEMALE; HUMANS; INTENSIVE CARE; LENGTH OF STAY; MALE; MIDDLE AGED; PARENTERAL NUTRITION, TOTAL; PRACTICE GUIDELINES; RENAL DIALYSIS; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 20944450298     PISSN: 13693786     EISSN: None     Source Type: Journal    
DOI: 10.1080/13693780410001731619     Document Type: Article

References (49)

1. Chen YC, Chang SC, Tai HM, Hsueh PR, Luh KT. Molecular epidemiology of Candida colonizing critically ill patients in intensive care units. J Formos Med Assoc 2001; 100: 791-797.
2. Berrouane YF, Herwaldt LA, Pfaller MA. Trends in antifungal use and epidemiology of nosocomial yeast infections in a university hospital. J Clin Microbiol 1999; 37: 531-537.
3. Rangel-Frausto MS, Wiblin T, Blumberg HM, et al. National epidemiology of mycoses survey (NEMIS): variations in rates of bloodstream infections due to Candida species in seven surgical intensive care units and six neonatal intensive care units. Clin Infect Dis 1999; 29: 253-258.
4. Jarvis WR. Epidemiology of nosocomial fungal infections, with emphasis on Candida species. Clin Infect Dis 1995; 20: 1526-1530.
5. Fraser VJ, Jones M, Dunkel J, et al. Candidemia in a tertiary care hospital: epidemiology, risk factors, and predictors of mortality. Clin Infect Dis 1992; 15: 414-421.
6. Jarvis WR, Martone WJ. Predominant pathogens in hospital infections. J Antimicrob Chemother 1992; 29(Suppl. A): 19-24.
7. Vincent JL, Anaissie E, Bruining H, et al. Epidemiology, diagnosis and treatment of systemic Candida infection in surgical patients under intensive care. Intensive Care Med 1998; 24: 206-216.
8. Taylor GD, Buchanan-Chell M, Kirkland T, McKenzie M, Wiens R. Trends and sources of nosocomial fungaemia. Mycoses 1994; 37: 187-190.
9. Ekenna O, Sherertz RJ, Bingham H. Natural history of blood-stream infections in a burn patient population: the importance of candidemia. Am J Infect Control 1993; 21: 189-195.
10. Chen YC, Lin SF, Liu CJ, et al. Risk factors for ICU mortality in critically ill patients. J Formos Med Assoc 2001; 100: 656-661.
11. Hoerauf A, Hammer S, Muller-Myhsok B, Rupprecht H. Intra-abdominal Candida infection during acute necrotizing pancreatitis has a high prevalence and is associated with increased mortality. Crit Care Med 1998; 26: 2010-2015.
12. Cornwell EE 3rd, Belzberg H, Offne TV, et al. The pattern of fungal infections in critically ill surgical patients. Am Surg 1995; 61: 847-850.
13. Leleu G, Aegerter P, Guidet B. Systemic candidiasis in intensive care units: a multicenter, matched-cohort study. J Crit Care 2002; 17: 168-175.
14. Pfaller MA, Jones RN, Doern GV, et al. Bloodstream infections due to Candida species: SENTRY antimicrobial surveillance program in North America and Latin America, 1997-1998. Antimicrob Agents Chemother 2000; 44: 747-751.
15. Rex JH, Sobel JD. Prophylactic antifungal therapy in the intensive care unit. Clin Infect Dis 2001; 32: 1191-1200.
16. Pfaller MA, Messer SA, Houston A, et al. National epidemiology of mycoses survey: a multicenter study of strain variation and antifungal susceptibility among isolates of Candida species. Diagn Microbiol Infect Dis 1998; 31: 289-296.
17. Petri MG, Konig J, Moecke HP, et al. Epidemiology of invasive mycosis in ICU patients: a prospective multicenter study in 435 non-neutropenic patients. Paul Ehrlich Society for Chemotherapy, Divisions of Mycology and Pneumonia Research. Intensive Care Med 1997; 23: 317-325.
18. Goodman JL, Winston DJ, Greenfield RA, et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med 1992; 326: 845-851.
19. Slavin MA, Osborne B, Adams R, et al. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation - a prospective, randomized, double-blind study. J Infect Dis 1995; 171: 1545-1552.
20. Rotstein C, Bow EJ, Laverdiere M, et al. Randomized placebo-controlled trial of fluconazole prophylaxis for neutropenic cancer patients: benefit based on purpose and intensity of cytotoxic therapy. The Canadian Fluconazole Prophylaxis Study Group. Clin Infect Dis 1999; 28: 331-340.
21. Ellis ME, Clink H, Ernst P, et al. Controlled study of fluconazole in the prevention of fungal infections in neutropenic patients with haematological malignancies and bone marrow transplant recipients. Eur J Clin Microbiol Infect Dis 1994; 13: 3-11.
22. Marr KA, Seidel K, Slavin MA, et al. Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: long-term follow-up of a randomized, placebo-controlled trial. Blood 2000; 96: 2055-2061.
23. Rex JH, Walsh TJ, Sobel JD, et al. Practice guidelines for the treatment of candidiasis. Infectious Diseases Society of America. Clin Infect Dis 2000; 30: 662-678.
24. Edwards JE Jr, Bodey GP, Bowden RA, et al. International Conference for the Development of a Consensus on the Management and Prevention of Severe Candida1 Infections. Clin Infect Dis 1997; 25: 43-59.
25. Savino JA, Agarwal N, Wry P, Policastro A, Cerabona T, Austria L. Routine prophylactic antifungal agents (clotrimazole, ketoconazole, and nystatin) in nontransplant/nonburned critically ill surgical and trauma patients. J Trauma 1994; 36: 20-25; discussion 25-26.
26. Ables A, Blumer NA, Valainis GT, Godenick MT, Kajdasz DK, Palesh YY. Fluconazole prophylaxis of severe Candida infection in trauma and postsurgical patients: A prospective, double-blind, randomized, placebo-controlled trial. Infect Dis Clin Pract 2000; 9: 169-175.
27. Pelz RK, Hendrix CW, Swoboda SM, et al. Double-blind placebo-controlled trial of fluconazole to prevent candida1 infections in critically ill surgical patients. Ann Surg 2001; 233: 542-548.
28. Eggimann P, Francioli P, Bille J, et al. Fluconazole prophylaxis prevents intra-abdominal candidiasis in high-risk surgical patients. Crit Care Med 1999; 27: 1066-1072.
29. Slotman GJ, Burchard KW. Ketoconazole prevents Candida sepsis in critically ill surgical patients. Arch Surg 1987; 122: 147-151.
30. Garbino J, Lew DP, Romand JA, Hugonnet S, Auckenthaler R, Pittet D. Prevention of severe Candida infections in nonneutropenic, high-risk, critically ill patients: a randomized, double-blind, placebo-controlled trial in patients treated by selective digestive decontamination. Intensive Care Med 2002; 28: 1708-1717.
31. Rocco TR, Reinert SE, Simms HH. Effects of fluconazole administration in critically ill patients: analysis of bacterial and fungal resistance. Arch Surg 2000; 135: 160-165.
32. Martins MD, Rex JH. Resistance to antifungal agents in the critical care setting: problems and perspectives. New Horiz 1996; 4: 338-344.
33. Voss A, le Noble JL, Verduyn Lunel FM, Foudraine NA, Meis JF. Candidemia in intensive care unit patients: risk factors for mortality. Infection 1997; 25: 8-11.
34. Sobel JD, Rex JH. Invasive candidiasis: turning risk into a practical prevention policy? Clin Infect Dis 2001; 33: 187-190.
35. Calandra T, Marchetti O. Antifungal prophylaxis for intensive care unit patients: let's fine tune it. Intensive Care Med 2002; 28: 1698-1700.
36. Blumberg HM, Jarvis WR, Soucie JM, et al. Risk factors for candida1 bloodstream infections in surgical intensive care unit patients: the NEMIS prospective multicenter study. The National Epidemiology of Mycosis Survey. Clin Infect Dis 2001; 33: 177-186.
37. Borzotta AP, Beardsley K. Candida infections in critically ill trauma patients: a retrospective case-control study. Arch Surg 1999; 134: 657-664; Discussion 664-665.
38. Pittet D, Monod M, Suter PM, Frenk E, Auckenthaler R. Candida colonization and subsequent infections in critically ill surgical patients. Ann Surg 1994; 220: 751-758.
39. Wey SB, Mori M, Pfaller MA, Woolson RF, Wenzel RP. Risk factors for hospital-acquired candidemia. A matched case-control study. Arch Intern Med 1989; 149: 2349-2353.
40. McKinnon PS, Goff DA, Kern JW, et al. Temporal assessment of Candida risk factors in the surgical intensive care unit. Arch Surg 2001; 136: 1401-1408; Discussion, 1409.
41. Wong DT, Knaus WA. Predicting outcome in critical care: the current status of the APACHE prognostic scoring system. Can J Anaesth 1991; 38: 374-383.
42. Ascioglu S, Rex JH, de Pauw B, et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002; 34: 7-14.
43. Mermel LA, Farr BM, Sherertz RJ, et al. Guidelines for the management of intravascular catheter-related infections. J Intraven Nurs 2001; 24: 180-205.
44. Bone RC, Balk RA, Cerra FB, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 1992; 101: 1644-1655.
45. Munoz P, Burillo A, Bouza E. Criteria used when initiating antifungal therapy against Candida spp. in the intensive care unit. Int J Antimicrob Agents 2000; 15: 83-90.
46. Fass RJ, Goff DA, Sierawski SJ. Candida infections in the surgical intensive care unit. J Antimicrob Chemother 1996; 38: 915-916.
47. Hedderwick SA, Lyons MJ, Liu M, Vazquez JA, Kauffman CA. Epidemiology of yeast colonization in the intensive care unit. Eur J Clin Microbiol Infect Dis 2000; 19: 663-670.
48. Krcmery VC Jr, Babela R. Candidemia in the surgical intensive care unit. Clin Infect Dis 2002; 34: 1537-1538.
49. Rentz AM, Halpern MT, Bowden R. The impact of candidemia on length of hospital stay, outcome, and overall cost of illness. Clin Infect Dis 1998; 27: 781-788.